Clinical Trial Update: A Canadian Open-Label Access Program to Evaluate Adalimumab When Added to Inadequate Therapy for the Treatment of Psoriasis [Phase 3]

View source ↗

Summary

This document reports the completion of a Phase 3 Canadian open-label study evaluating adalimumab added to inadequate therapy for psoriasis, with results posted…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Psoriasis

Drugs mentioned

• Humira (adalimumab)

Snippet

Sponsor: Abbott | Conditions: Psoriasis | Phase 3 | Status: COMPLETED | Results posted: 2009-11-20